Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2012

IntelliCell Licenses SVF Manufacturing Technology to Cell-Innovations

  • Cell-Innovations will market the stromal vascular fraction (SVF) manufacturing technology of IntelliCell BioSciences in Australia and New Zealand, under a license agreement that calls for a one-time payment of $700,000 and a royalty stream of 12.5% of net sales.

    IntelliCell’s technology is a nonenzymatic method for deriving SVF containing adult stem cells from 60 cc’s of adipose tissue. According to the company, the technology generates between half billion to 1.4 billion SVF cells, about 10–20 times greater than present-day enzyme-based methods.

    Cell-Innovations and IntelliCell also say they will assist Macquarie Stem Cells, a company of Cell-Innovations director Ralph Bright, to establish IntelliCell Centers of Excellence where doctors can treat their patients.

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »